Technical Study: Cell Therapeutics Inc., ACADIA Pharmaceuticals Inc., Sarepta Therapeutics Inc., and Medivation Inc.

Technical Study: Cell Therapeutics Inc., ACADIA Pharmaceuticals Inc., Sarepta
                    Therapeutics Inc., and Medivation Inc.

PR Newswire

LONDON, September 25, 2013

LONDON, September 25, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

The U.S. equity market closed on a mixed note on Tuesday, September 24, 2013.
The S&P 500 and the Dow Jones Industrial Average ended lower, while the NASDAQ
Composite posted gains. Shares in the biotechnology industry mostly ended on a
higher note, even as the broader market fluctuated between gains and losses.
Cell Therapeutics Inc. (NASDAQ: CTIC), ACADIA Pharmaceuticals Inc. (NASDAQ:
ACAD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), and Medivation Inc. (NASDAQ:
MDVN), were amongst the major movers. AAAResearchReports.com free coverage on
CTIC, ACAD, SRPT, and MDVN is available upon registration at:

http://www.aaaresearchreports.com/register/

Shares in Cell Therapeutics Inc. surged 3.56% on Tuesday, extending the gains
from the previous trading session. The company's shares fluctuated
between$1.58 and $1.77before ending the day at$1.60. A total of 7.51
million shares were traded, which is above the daily average volume of 1.49
million. The company's shares have rallied 46.79% in the previous three months
and 39.13% in the last one month, outperforming the S&P 500 which has gained
7.90% and 2.04% during the respective periods. Moreover, Cell Therapeutics
Inc.'s stock is currently trading above its 50-day and 200-day moving averages
of $1.13 and $1.22, respectively. Download free technical research on CTIC by
signing up at:

http://www.AAAResearchReports.com/CTIC092513.pdf

ACADIA Pharmaceuticals Inc.'s shares rose sharply on Tuesday, even as the
broader market finished on a mixed note. The company's shares closed the day
1.30% higher at $24.94 after oscillating between$24.40 and $25.11 during the
trading session. A total of 1.12 million shares were traded, which is below
the daily average volume of 2.17 million. The company's stock has rallied
42.68% in the last three months and 20.89% in the previous one month, compared
to a gain of 7.90% and 2.04% in the S&P 500 during the respective periods.
Additionally, ACADIA Pharmaceuticals Inc.'s shares are trading near their
52-week high of $25.50 as well as above their 50-day and 200-day moving
averages of $20.88 and $12.68, respectively. Register now and get access to
free analysis on ACAD at:

http://www.AAAResearchReports.com/ACAD092513.pdf

Sarepta Therapeutics Inc.'s stock fell by 0.75% on Tuesday, reversing some
gains from its rally in the previous trading session. The company's shares
oscillated between$46.63 and $48.78before ending the day at $47.61. A total
of 2.69 million shares were traded, which is above the daily average volume of
1.95 million. The company's shares have rallied 29.76% in the previous three
trading sessions and 41.49% in the last one month, compared to a loss of 1.45%
and a gain of 2.04% in the S&P 500 during the respective periods. Moreover,
Sarepta Therapeutics Inc.'s stock is currently trading above its 50-day and
200-day moving averages of $37.12 and $33.41, respectively. Sign up and read
our complimentary report on SRPT at:

http://www.AAAResearchReports.com/SRPT092513.pdf

On Tuesday, Medivation Inc.'s stock advanced to close at $57.47, up 0.21% from
the previous day's closing price of $57.35. The company's shares oscillated
between $56.91 and $57.91 during the trading session. A total of 0.31 million
shares were traded, which is below the daily average volume of 0.89 million.
The company's shares have rallied 25.10% in the previous three months,
outperforming the S&P 500 which has gained 7.90% during the same period.
Additionally, Medivation Inc.'s stock is trading above its 50-day and 200-day
moving averages of $57.42 and $52.80, respectively. The free report on MDVN
can be downloaded by signing up now at:

http://www.AAAResearchReports.com/MDVN092513.pdf

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AAAresearchreports.com

SOURCE AAA Research Reports

Contact: Media Contact: Peter F. Jones, Phone #: +1-(646)396-9126, Email ID:
info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.